Frank Saran1, Olivier L Chinot1, Roger Henriksson1, Warren Mason1, Wolfgang Wick1, Timothy Cloughesy1, Sunita Dhar1, Emanuela Pozzi1, Josep Garcia1, Ryo Nishikawa1. 1. The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK (F.S.); Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France (O.L.C.); Regional Cancer Center, Stockholm-Gotland, Karolinska University Hospital, Stockholm, Sweden (R.H.); Department of Radiation Sciences and Oncology, Umeå University, Förvaltningshuset, Universitetstorget, Umeå, Sweden (R.H.); Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada (W.M.); University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W.); University of California, Los Angeles, California, USA (T.C.); Genentech Inc., South San Francisco, California, USA (S.D.); F. Hoffmann-La Roche Ltd, Basel, Switzerland (E.P., J.G.); Saitama Medical University, Saitama, Japan (R.N.).
Abstract
BACKGROUND: The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns. Bevacizumab has been linked with stroke, bleeding events, and wound-healing complications in other tumor types; these events are of particular concern for glioblastoma (highly vascular tumors that are usually resected). Published data on the interaction of bevacizumab with radiotherapy/temozolomide are also limited. We report safety data from a phase III randomized trial (Avastin in Glioblastoma), focusing on these considerations. METHODS: Eligible patients received: radiotherapy and temozolomide plus bevacizumab/placebo, 6 cycles; a 4-week treatment break; temozolomide plus bevacizumab/placebo, 6 cycles; and bevacizumab/placebo until progression. Data on adverse events (AEs) were collected throughout. RESULTS:Bevacizumab-treated patients (n = 461) had a longer median safety follow-up time (12.3 vs 8.5 mo), and a higher proportion completed 6 cycles of maintenance temozolomide (64.6% vs 36.9%) versus placebo (n = 450). The incidences of relevant AEs (bevacizumab vs placebo, respectively) were: arterial thromboembolic events (5.9% vs 1.6%); cerebral hemorrhage (3.3% vs 2.0%); wound-healing complications (6.9% vs 4.7%); thrombocytopenia (34.1% vs 27.3%); radiotherapy-associated skin injury (8.2% vs 9.3%); alopecia (39.0% vs 36.0%); gastrointestinal perforation (including gastrointestinal abscesses and fistulae, 1.7% vs 0.4%); and radiotherapy-associated injury (0.4% vs 0.0%). Overall, 15.8% and 23.8% of bevacizumab- and placebo-treated patients had surgery (including biopsy) after progression. Within 30 days of postprogression surgery, AE incidence was 10.9% (bevacizumab) and 23.4% (placebo). CONCLUSION: The safety profile was consistent with that expected from radiotherapy/temozolomide plus bevacizumab. The increased AE incidence with bevacizumab did not impact patients' ability to receive standard-of-care treatment or to undergo further surgery.
RCT Entities:
BACKGROUND: The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns. Bevacizumab has been linked with stroke, bleeding events, and wound-healing complications in other tumor types; these events are of particular concern for glioblastoma (highly vascular tumors that are usually resected). Published data on the interaction of bevacizumab with radiotherapy/temozolomide are also limited. We report safety data from a phase III randomized trial (Avastin in Glioblastoma), focusing on these considerations. METHODS: Eligible patients received: radiotherapy and temozolomide plus bevacizumab/placebo, 6 cycles; a 4-week treatment break; temozolomide plus bevacizumab/placebo, 6 cycles; and bevacizumab/placebo until progression. Data on adverse events (AEs) were collected throughout. RESULTS:Bevacizumab-treated patients (n = 461) had a longer median safety follow-up time (12.3 vs 8.5 mo), and a higher proportion completed 6 cycles of maintenance temozolomide (64.6% vs 36.9%) versus placebo (n = 450). The incidences of relevant AEs (bevacizumab vs placebo, respectively) were: arterial thromboembolic events (5.9% vs 1.6%); cerebral hemorrhage (3.3% vs 2.0%); wound-healing complications (6.9% vs 4.7%); thrombocytopenia (34.1% vs 27.3%); radiotherapy-associated skin injury (8.2% vs 9.3%); alopecia (39.0% vs 36.0%); gastrointestinal perforation (including gastrointestinal abscesses and fistulae, 1.7% vs 0.4%); and radiotherapy-associated injury (0.4% vs 0.0%). Overall, 15.8% and 23.8% of bevacizumab- and placebo-treated patients had surgery (including biopsy) after progression. Within 30 days of postprogression surgery, AE incidence was 10.9% (bevacizumab) and 23.4% (placebo). CONCLUSION: The safety profile was consistent with that expected from radiotherapy/temozolomide plus bevacizumab. The increased AE incidence with bevacizumab did not impact patients' ability to receive standard-of-care treatment or to undergo further surgery.
Authors: Albert Lai; Anh Tran; Phioanh L Nghiemphu; Whitney B Pope; Orestes E Solis; Michael Selch; Emese Filka; William H Yong; Paul S Mischel; Linda M Liau; Surasak Phuphanich; Keith Black; Scott Peak; Richard M Green; Cynthia E Spier; Tatjana Kolevska; Jonathan Polikoff; Louis Fehrenbacher; Robert Elashoff; Timothy Cloughesy Journal: J Clin Oncol Date: 2010-12-06 Impact factor: 44.544
Authors: Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa Journal: J Neurosurg Date: 2012-10-05 Impact factor: 5.115
Authors: Terri S Armstrong; Yumei Cao; Michael E Scheurer; Elizabeth Vera-Bolaños; Rochelle Manning; Mehmet F Okcu; Melissa Bondy; Renke Zhou; Mark R Gilbert Journal: Neuro Oncol Date: 2009-12 Impact factor: 12.300
Authors: Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Klaus Christian Mende; Jakob Matschke; Till Burkhardt; Wolfgang Saeger; Rolf Buslei; Michael Buchfelder; Rudolf Fahlbusch; Manfred Westphal; Jörg Flitsch Journal: CNS Neurosci Ther Date: 2017-05-28 Impact factor: 5.243
Authors: Eric W Sankey; Vadim Tsvankin; Matthew M Grabowski; Gautam Nayar; Kristen A Batich; Aida Risman; Cosette D Champion; April K S Salama; C Rory Goodwin; Peter E Fecci Journal: Cancer Med Date: 2019-09-30 Impact factor: 4.452
Authors: Rayana L Bighetti-Trevisan; Lucas O Sousa; Rogerio M Castilho; Luciana O Almeida Journal: Stem Cells Int Date: 2019-11-12 Impact factor: 5.443